MAPT and supranuclear palsy, progressive, 1: In this clinically oriented flowchart, we propose “midbrain atrophy” as a neuroimaging marker in NPH patients, “closely observe if there is PSP‐like feature” from the clinical perspective, and “Tau PET” (if accessible) from the biochemical direction.